Effect of Genetic Alterations Affecting the Genes Encoding the Major Enzymes of the Kynurenine Pathway on Suicidal Behavior

Completed

• Conditions: Tryptophan Metabolism Alterations; Polymorphism; Suicidal Behavior
• Interventions: Genetic: Analysis of Single nucleotide polymorphisms in each group.

• Registration Number: NCT04565834
• Lead Sponsor: Centre Hospitalier Universitaire de Nīmes

Brief Summary

Current research has shown that an imbalance in the Kynurenine pathway plays a role in the physiopathology of neurogenerative and mental disorders (with a decrease in neuroprotective metabolites and an increase in neurotoxic products). So far the research has concentrated on the enzymes IDO 1/2, KAT (1-4), KMO and ACMSD which are the key players in this pathway. Several polymorphisms affecting these enzymes have been associated with certain disorders characterized by a deregulation of the inflammation and immune response (McCauley et al 2009,Tardito et al 2013, Lee et al 2014), but the link between these enzymes and suicidal behavior is not yet clear. The investigators hypothesize that people with history of suicide attempt would have a genetic alterations of the kynurenine pathway specific for suicidal behavior.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-12-01
• Study First Submitted: 2020-09-14
• Study First Submitted QC: 2020-09-24
• Study First Posted: 2020-09-25
• Primary Completion: 2023-03-01
• Study Completion: 2023-03-01
• Status Verified: 2023-06
• Last Update Submitted: 2025-02-11
• Last Update Posted: 2025-02-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 849

Inclusion Criteria

• For the "Sucide attempters" group: Any patient aged 18 or over who has made at least one suicide attempt.
• For the two control groups: Any patient aged 18 or over, suffering from depression but has never attempted to commit suicide and any healthy subject who has never had any mental disorders.

Exclusion Criteria

• Any patient who has expressed opposition to the use of his/her data.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Suicidal patients	Analysis of Single nucleotide polymorphisms in each group.	Patients who have made at least one attempt to commit suicide.
Control group	Analysis of Single nucleotide polymorphisms in each group.	This group will consist of two types of people: * 75 healthy subjects (i.e. those who have no mental disorders and have never attempted to commit suicide) and * 150 patients suffering from depression but have never attempted to commit suicide.

Primary Outcome Measures

Name	Time	Method
The genotypic and allelelic frequencies of IDO1 rs7820268 SNP in each studied group	24 months	The frequencies of this SNP will be measured as a percentage
The genotypic and allelelic frequencies of IDO2 rs10109853 SNP in each studied group	24 months	The frequencies of this SNP will be measured as a percentage
The genotypic and allelelic frequencies of KMO rs1053230 SNP in each studied group	24 months	The frequencies of this SNP will be measured as a percentage
The genotypic and allelelic frequencies of KAT1 rs10988134 SNP in each studied group	24 months	The frequencies of this SNP will be measured as a percentage
The genotypic and allelelic frequencies of ACMSD rs2121337 SNP in each studied group	24 months	The frequencies of this SNP will be measured as a percentage

Trial Locations

Locations (2)

Department of Psychiatry, Nimes University Hospital; 🇫🇷 Nîmes, Gard, France

José-Fernandez-Piqueras; 🇪🇸 Madrid, Spain